Vor looks to answer the Car-T question
Can the company add a Car-T string to its stem cell transplant bow?
Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
The first clinical-stage dual-payload conjugate
Chengdu Kanghong's KH815 enters human testing this month.
Compass claims a pivotal win with tovecimig
A biliary tract cancer trial hits on response rate, but survival data will be key.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
Aura bids to join the bladder cancer crowd
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
